Abstract
Influenza vaccination is now recommended for all ages; CDC pneumococcal polysaccharide vaccination (PPV) recommendations are comorbidity-based in nonelderly patients. We constructed a Markov model to estimate the cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds. Patients were followed for 10 years, with differing time horizons examined in sensitivity analyses. With 100% vaccine uptake, dual vaccination cost $37,700/QALY gained compared to a CDC recommendation strategy; with observed vaccine uptake, dual vaccination cost $5,300/QALY. Results were sensitive to shorter time horizons, favoring CDC recommendations. We found dual vaccination of all 50-year-olds economically reasonable. Shorter duration models may not fully account for PPV effectiveness.
Original language | English (US) |
---|---|
Pages (from-to) | 7620-7625 |
Number of pages | 6 |
Journal | Vaccine |
Volume | 28 |
Issue number | 48 |
DOIs | |
State | Published - Nov 10 2010 |
Externally published | Yes |
Keywords
- Cost-effectiveness
- Influenza vaccine
- Pneumococcal polysaccharide vaccine
- Secondary pneumococcal pneumonia
ASJC Scopus subject areas
- Molecular Medicine
- Immunology and Microbiology(all)
- veterinary(all)
- Public Health, Environmental and Occupational Health
- Infectious Diseases